Auditor (@auditor112017) profile picture

Auditor

@auditor112017

Retired Internal Auditor (CISA), Accountant, and Info Sec Engineer. Followed biotech, pharma, banking and tech sectors for more than 25 years.

Joined October 2017
  • Tweets5.9K
  • Following45
  • Followers310
636Media
Photo by Auditor (@auditor112017)Photo by Auditor (@auditor112017)Photo by Auditor (@auditor112017)Photo by Auditor (@auditor112017)Photo by Auditor (@auditor112017)Photo by Auditor (@auditor112017)Photo by Auditor (@auditor112017)Photo by Auditor (@auditor112017)Photo by Auditor (@auditor112017)Photo by Auditor (@auditor112017)
HIBSAGO should play a larger part in $IONS revenue. Per 10Q: "In October 2026, we achieved a $30 million milestone payment when the FDA approved HIBSAGO for the treatment of CHB infection. We will achieve the next payment of up to $35 million if HIBSAGO is approved in China."
1
115
$IONS $BIIB $NVS biopharmadive.com/news/zolge…
Novartis reveals cancer cases possibly linked to gene therapy Zolgensma

Novartis reveals cancer cases possibly linked to gene therapy Zolgensma

The occurrence of cancer in nine recipients — two of which involved evidence that a viral delivery tool integrated into patient DNA — could raise new questions for the gene therapy field.

biopharmadive.com
1
148
$IONS $BIIB $NVS With couple of drugs available now in the market, not sure if this treatment benefit would outweigh the potential risks.
Image from Auditor (@auditor112017)
89
$IONS is learning how to sell a new treatment for sHTG. Their sales estimate was too high for a new treatment. It is harder to change change physician behavior and patient selection. They should have learned from the slow launches from PCSK9, ATTR, and other rare diseases.
2
182
$IONS $BIIB $NVS Novartis Reports Previously Unknown Tumor Cases Possibly Linked to SMA Gene Therapy trial.medpath.com/news/novar…
Novartis Reports Seven Previously Unknown Tumor Cases in Children Treated With Zolgensma - MedPath...

Novartis Reports Seven Previously Unknown Tumor Cases in Children Treated With Zolgensma - MedPath...

Novartis has acknowledged seven previously unknown instances of tumors in children treated with its spinal muscular atrophy gene...

trial.medpath.com
1
328
$IONS ir.ionis.com/news-releases/n…

Ionis to hold third quarter 2026 financial results webcast | Ionis Pharmaceuticals, Inc.

The Investor Relations website contains information about Ionis Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts.

ir.ionis.com
1
339
$WVE Looking forward to Wave’s 2026 Virtual Research Day Nov 4, 2026 9:30 AM EST
1
1
244
$IONS $BIIB Surprising to see Spinraza sales increased! finance.yahoo.com/markets/st…
Image from Auditor (@auditor112017)
1
5
580
$BIIB partnered Spinraza and Qalsody with $ions.
Image from Auditor (@auditor112017)
1
287
$IONS finance.yahoo.com/healthcare…
Ionis ranked #1 on Science’s Top Employers list

Ionis ranked #1 on Science’s Top Employers list

CARLSBAD, Calif., October 22, 2026--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the company was named the top employer to work for by Science in its annual Top Employers survey of...

finance.yahoo.com
112
$IONS $GSK Probably should keep an eye on the Japan market to see how well this drug is accepted by patients there. fiercepharma.com/pharma/gsk-…
GSK brings promise of 'functional cure' to hepatitis B finish line with FDA nod for Hibsago

GSK brings promise of 'functional cure' to hepatitis B finish line with FDA nod for Hibsago

With the FDA’s green light in hepatitis B, GSK and its Ionis-licensed medicine bepirovirsen have racked up several notable distinctions, bringing the antisense oligonucleotide class to bear against |...

fiercepharma.com
1
134
$IONS Per BM on the recent MS webcast, the goal is to protect TRYNGOLZA franchise and he is shooting for ph3 for ION775 (siRNA) by end of 2027. Looks very optimistic! But should be interesting to see if the drug will have a 6mos or 1yr dosing.
2
158
$IONS $PRAX should have a ph3 data readout by year end or early next yr for Elsunersen. Very confusing partnership! clinicaltrials.gov/study/NCT… ir.praxismedicines.com/news-…
1
519
$IONS $PRAX Looks like Elsunersen qualifies for the Rare Pediatric Disease Priority Review Voucher (PRV).
452
$IONS Good news keep on coming in one after another! Looks like they are seeing something really good here to use words like "best-in-class potential"! ir.ionis.com/news-releases/n…

Ionis announces positive interim data from partner Roche’s Phase 3 IMAgINATION study in IgA...

The Investor Relations website contains information about Ionis Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts.

ir.ionis.com
157
$IONS fiercebiotech.com/biotech/ot…
Otsuka heads to FDA as Ionis-partnered ALS drug hits primary phase 3 endpoint

Otsuka heads to FDA as Ionis-partnered ALS drug hits primary phase 3 endpoint

A phase 3 study of Otsuka and Ionis Pharmaceuticals’ amyotrophic lateral sclerosis (ALS) drug candidate has 

fiercebiotech.com
1
2
405
$IONS Is this a misprint? Seems like a huge amount: $221 m in 2026 for Ionis on hep B!
Image from Auditor (@auditor112017)
1
236
I've started to load up on $IONS again. Has been waiting for this moment!
261
$IONS is now facing a hard question on whether to advance their siRNA for Lp(a) to CT or scrap the program and use the resource for other programs.
1
251
$IONS fiercepharma.com/pharma/ioni…
Ionis’ ‘breakthrough’ Alexander disease approval establishes pillar of rare disease pipeline

Ionis’ ‘breakthrough’ Alexander disease approval establishes pillar of rare disease pipeline

After Jenny Pearson’s daughter Elise first had a seizure at 16 months old, an MRI came back clean—her brain “looked beautiful,” Pearson recalled to Fierce. | After Jenny Pearson’s daughter Elise...

fiercepharma.com
1
214
$IONS Angelman drug is much more potent and has better safety profile than $rare !
Image from Auditor (@auditor112017)
1
1
388
$rare Angelman failure likely due to lower dosing regimen due to safety issue. $ions
Image from Auditor (@auditor112017)
1
271
$IONS Looks like ION775 could go annual dosing!
Image from Auditor (@auditor112017)
Image from Auditor (@auditor112017)
2
5
857
$IONS I could see them doing an annual for the moderate HTG patient population: approx. 25–35 million!
202
$ions $gsk Bepirovirsen (Hep B) could get approved (PDUFA date: Oct 26, 2026) before Pelacarsen (Lp(a)) ph3 data readout!
3
491
Looks like $ions and $azn could salvage from the failed ATTR-cm ph 3 trial by directing the ATTR-cm positive mono-therapy subgroup data to ATTR-pn. It strengthens the case that ATTR‑PN, is likely beneficial for mixed‑phenotype patients. Should start a CT for ATTR‑pn/cm!
3
2
685
Looks like silencers like Eplontersen is the ideal drug to treat this mixed‑phenotype patients; not stabilizers. $ions $azn
Image from Auditor (@auditor112017)
1
462

No more items